It is true that when you have discussed p values and other relevant measurements, you have not accounted for the almost certain higher performance of 2-73 in future, targeted trials screened for best dosage and best genetic subjects. Consequently, your conclusions appear to undervalue its projectable performance.
I will note here, for the record, that the PDD trial seems to have somewhat exceeded the expectations you set forth several months ago.